Journal of Pharmacokinetics and Pharmacodynamics

Papers
(The H4-Index of Journal of Pharmacokinetics and Pharmacodynamics is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions43
Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during34
Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models32
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine31
Enabling pregnant women and their physicians to make informed medication decisions using artificial intelligence26
Two heads are better than one: current landscape of integrating QSP and machine learning25
Fast screening of covariates in population models empowered by machine learning25
Challenges in conducting clinical research studies in pregnant women22
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration22
Recent applications of quantitative systems pharmacology and machine learning models across diseases22
A kinetic proofreading model for bispecific protein degraders21
Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-220
Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance19
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations18
Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling18
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases16
Population pharmacokinetic model selection assisted by machine learning16
0.079405069351196